PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer.

PolyPid has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. She will step down from the Board of Directors. Dr. Tweezer-Zaks brings extensive medical expertise and industry experience, making her well-suited to lead the company's medical strategy as it prepares for its NDA submission and advances its pipeline.

PolyPid (NASDAQ:PYPD), a late-stage biopharma company, has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks will step down from her current role on PolyPid's Board of Directors, which she has held since November 2023. This appointment comes on the heels of positive Phase 3 SHIELD II trial results and is a strategic move as the company prepares for its New Drug Application (NDA) submission.

Dr. Tweezer-Zaks brings significant experience from her roles as CEO of MediCane Health Inc., CMO at aMOON Venture Capital Fund, and various positions at Sanofi. She has also practiced as a physician at Sheba Medical Center for 15 years. Her extensive background in medical and executive roles makes her well-suited to lead PolyPid's medical strategy.

"This appointment is a significant milestone for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Dr. Tweezer-Zaks' expertise and experience will be invaluable as we prepare for our NDA submission and advance our pipeline."

Dr. Tweezer-Zaks holds an M.D. and B.S. from Ben-Gurion University School of Medicine in Beer Sheva, Israel, and an M.B.A. from the Kellogg-Recanati International Executive MBA Program. She is excited to join PolyPid's executive team at this transformative moment for the company.

PolyPid's proprietary PLEX technology, which pairs with Active Pharmaceutical Ingredients (APIs) for precise drug delivery, is the foundation of its pipeline. Following positive phase 3 results, the company expects to submit its NDA for D-PLEX100, a lead product candidate for the prevention of abdominal colorectal surgical site infections, in early 2026. Additionally, the company has an innovative pipeline in oncology, obesity, and diabetes.

References:
[1] https://www.stocktitan.net/news/PYPD/poly-pid-appoints-dr-nurit-tweezer-zaks-as-chief-medical-w1flir72kdqr.html